HEPA

Hepion Pharmaceuticals (HEPA)

Hepion Pharmaceuticals Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:HEPA

1 2 3 4 5 6 7 8 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/22	06:08	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2024/05/16	05:46	Edgar (US Regulatory)	Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2024/04/20	05:30	GlobeNewswire Inc.	Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2024/02/16	23:02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2024/02/16	22:00	GlobeNewswire Inc.	Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2024/02/15	05:38	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2024/01/04	07:15	GlobeNewswire Inc.	Hepion Pharmaceuticals to Present at NASH-TAG 2024	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2024/01/04	06:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/12/07	22:00	GlobeNewswire Inc.	Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/11/29	06:15	GlobeNewswire Inc.	Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/11/14	06:05	GlobeNewswire Inc.	Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/11/10	22:50	GlobeNewswire Inc.	Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/11/09	14:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/10/25	21:30	GlobeNewswire Inc.	Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/09/29	21:00	GlobeNewswire Inc.	Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/09/22	05:05	GlobeNewswire Inc.	Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/09/21	21:00	GlobeNewswire Inc.	New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening Program	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/09/19	22:00	GlobeNewswire Inc.	Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/09/18	21:00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/09/14	21:45	GlobeNewswire Inc.	Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/09/07	05:40	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/09/07	05:30	GlobeNewswire Inc.	Hepion Pharmaceuticals Announces Management Changes	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/07/25	05:04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/07/22	05:41	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/07/22	05:39	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/06/16	05:45	GlobeNewswire Inc.	Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/06/15	21:22	GlobeNewswire Inc.	Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/05/25	05:45	GlobeNewswire Inc.	Hepion Pharmaceuticals to Highlight AI-POWR™ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical Sciences	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/05/22	20:00	GlobeNewswire Inc.	Hepion Pharmaceuticals’ Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers	NASDAQ:HEPA	Hepion Pharmaceuticals Inc
2023/05/20	05:05	GlobeNewswire Inc.	Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat	NASDAQ:HEPA	Hepion Pharmaceuticals Inc